Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years.
Journal: Human vaccines & immunotherapeutics
Published: May 29, 2026
Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants.
Journal: Open forum infectious diseases
Published: June 10, 2025
Erratum to "INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(1): 100005.].
Journal: The journal of prevention of Alzheimer's disease
Published: June 01, 2025
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Journal: The journal of prevention of Alzheimer's disease
Published: October 16, 2024
Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).
Journal: Menopause (New York, N.Y.)
Published: April 16, 2024
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Journal: Diabetes, obesity & metabolism
Published: December 13, 2023
Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study.
Journal: Journal of child and adolescent psychopharmacology
Published: July 12, 2023
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
Journal: The New England journal of medicine
Published: October 19, 2022
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
Journal: The Journal of clinical endocrinology and metabolism
Published: May 26, 2022
Showing 1-10 of 10
Last Updated: 09/26/2026